SitesBLAST

SitesBLAST – Find functional sites

SitesBLAST

Comparing 13241 to proteins with known functional sites using BLASTp with E ≤ 0.001.

Or try Sites on a Tree, PaperBLAST, Conserved Domains, or compare to all protein structures

Found 20 (the maximum) hits to proteins with known functional sites (download)

J9VE33 Transcriptional regulator CRZ1 from Cryptococcus neoformans var. grubii serotype A (strain H99 / ATCC 208821 / CBS 10515 / FGSC 9487) (Filobasidiella neoformans var. grubii) (see 2 papers)
59% identity, 100% coverage: 1:77/77 of query aligns to 944:1025/1094 of J9VE33

query
sites
J9VE33

F

F

V

K

C

C

E

P

L

V

-

P

-

G

C

C

G

G

E

S

T

T

F

F

T

T

R

R

R

H

Y

F

N

N

L

L

R

K

G

G

H

H

Q

L

R

R

A

S

H

H

K

N

G

D

E

E

K

R

P

P

Y

F

K

K

C

C

S

L

Y

Y

E

E

G

G

C

C

D

P

K

K

A

A

-

I

-

V

-

G

F

F

A

A

R

R

A

Q

H

H

D

D

C

C

K

K

R

R

H

H

E

M

L

L

H

H

L

E

G

G

V

L

R

R

K

L

Y

F

H

E

C

C

S

E

P

G

C

C

N

G

R

K

D

K

F

F

V

A

R

R

L

L

D

D

A

A

L

L

H

T

R

R

H

H

Sites not aligning to the query:

103 modified: Phosphoserine
288 modified: Phosphoserine; S→A: Increases CRZ1 localization to the nucleus.
329 modified: Phosphoserine
451:456 mutation Missing: Abolishes nuclear localization during heat stress and confers sensitivity to high temperature, Congo Red and sodium dodecyl sulfate.
508 modified: Phosphoserine; S→A: Increases CRZ1 localization to the nucleus.
569 modified: Phosphoserine
765 modified: Phosphoserine
810 modified: Phosphoserine

Q09838 Transcriptional regulator prz1; Pbp1-responsive zinc finger protein 1 from Schizosaccharomyces pombe (strain 972 / ATCC 24843) (Fission yeast) (see paper)
47% identity, 100% coverage: 1:77/77 of query aligns to 570:646/681 of Q09838

query
sites
Q09838

F

Y

V

V

C

C

E

T

L

F

-

A

-

G

C

C

G

N

E

K

T

R

F

F

T

T

R

R

R

A

Y

Y

N

N

L

L

R

K

G

S

H

H

Q

M

R

N

A

T

H

H

K

T

G

N

E

Y

K

R

P

P

Y

F

K

Q

C

C

S

S

Y

I

E

-

G

-

C

C

D

K

K

K

A

S

F

F

A

A

R

R

A

Q

H

H

D

D

C

K

K

R

R

R

H

H

E

E

L

Q

L

L

H

H

L

T

G

G

V

I

R

K

K

A

Y

F

H

A

C

C

S

V

P

T

C

C

N

N

R

Q

D

R

F

F

V

A

R

R

L

M

D

D

A

A

L

L

H

N

R

R

H

H

Sites not aligning to the query:

543 modified: Phosphoserine
546 modified: Phosphoserine

O95600 Krueppel-like factor 8; Basic krueppel-like factor 3; Zinc finger protein 741 from Homo sapiens (Human) (see 2 papers)
43% identity, 94% coverage: 6:77/77 of query aligns to 281:352/359 of O95600

query
sites
O95600

C

C

G

S

E

K

T

V

F

Y

T

T

R

K

R

S

Y

S

N

H

L

L

R

K

G

A

H

H

Q

R

R

R

A

I

H

H

K

T

G

G

E

E

K

K

P

P

Y

Y

K

K

C

C

S

T

Y

W

E

D

G

G

C

C

D

S

K

W

A

K

F

F

A

A

R

R

A

S

H

D

D

E

C

L

K

T

R

R

H

H

E

F

L

R

L

K

H

H

L

T

G

G

V

I

R

K

K

P

Y

F

H

R

C

C

S

T

P

D

C

C

N

N

R

R

D

S

F

F

V

S

R

R

L

S

D

D

A

H

L

L

H

S

R

L

H

H

Sites not aligning to the query:

67 K→R: Abolishes sumoylation. No change in nuclear location. Increases transcriptional activity and cell cycle progression. Abolishes sumoylation; when associated with R-217.
85:93 9aaTAD; inactive
217 K→R: No change in sumoylation. Abolishes sumoylation; when associated with R-67.

Q60980 Krueppel-like factor 3; Basic krueppel-like factor; CACCC-box-binding protein BKLF; TEF-2 from Mus musculus (Mouse) (see 2 papers)
45% identity, 92% coverage: 6:76/77 of query aligns to 266:338/344 of Q60980

query
sites
Q60980

C

C

G

N

E

K

T

V

F

Y

T

T

R

K

R

S

Y

S

N

H

L

L

R

K

G

A

H

H

Q

R

R

R

A

T

H

H

K

T

G

G

E

E

K

K

P

P

Y

Y

K

K

C

C

S

T

Y

W

E

E

G

G

C

C

D

T

K

W

A

K

F

F

A

A

R

R

A

S

H

D

D

E

C

L

K

T

R

R

H

H

E

F

L

R

L

K

H

H

L

T

G

G

V

I

R

K

K

P

Y

F

H

Q

C

C

S

P

P

D

C

C

N

D

R

R

D

S

F

F

V

S

R

R

L

S

D

D

-

H

-

L

A

A

L

L

H

H

R

R

Sites not aligning to the query:

10 modified: Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO); K→A: Reduced sumoylation levels. No effect on DNA-binding and slight reduction of transcriptional repression. Abolishes sumoylation. No effect on DNA-binding but great reduction in transcriptional repression; when associated with A-197.
12 E→A: Slight reduction of transcriptional repression. Great reduction of transcriptional repression; when associated with A-199.
197 K→A: Reduced sumoylation levels. No effect on DNA-binding and slight reduction of transcriptional repression. Abolishes sumoylation. No effect on DNA-binding but great reduction of transcriptional repression; when associated with A-10.
199 E→A: Slight reduction of transcriptional repression. Great reduction of transcriptional repression; when associated with A-199.
341 mutation H->A,D,E,N,Q,R: Little change in DNA-binding ability.

Q13887 Krueppel-like factor 5; Basic transcription element-binding protein 2; BTE-binding protein 2; Colon krueppel-like factor; GC-box-binding protein 2; Intestinal-enriched krueppel-like factor; Transcription factor BTEB2 from Homo sapiens (Human) (see 3 papers)
46% identity, 94% coverage: 6:77/77 of query aligns to 380:451/457 of Q13887

query
sites
Q13887

C

C

G

T

E

K

T

V

F

Y

T

T

R

K

R

S

Y

S

N

H

L

L

R

K

G

A

H

H

Q

L

R

R

A

T

H

H

K

T

G

G

E

E

K

K

P

P

Y

Y

K

K

C

C

S

T

Y

W

E

E

G

G

C

C

D

D

K

W

A

R

F

F

A

A

R

R

A

S

H

D

D

E

C

L

K

T

R

R

H

H

E

Y

L

R

L

K

H

H

L

T

G

G

V

A

R

K

K

P

Y

F

H

Q

C

C

S

G

P

V

C

C

N

N

R

R

D

S

F

F

V

S

R

R

L

S

D

D

A

H

L

L

H

A

R

L

H

H

Sites not aligning to the query:

118:126 9aaTAD
301 P → S: in a colorectal cancer sample; somatic mutation
324:328 Interaction with WWP1; mutation Missing: Impairs ubiquitination and degradation.

P57682 Krueppel-like factor 3; Basic krueppel-like factor; CACCC-box-binding protein BKLF; TEF-2 from Homo sapiens (Human) (see paper)
45% identity, 92% coverage: 6:76/77 of query aligns to 267:339/345 of P57682

query
sites
P57682

C

C

G

N

E

K

T

V

F

Y

T

T

R

K

R

S

Y

S

N

H

L

L

R

K

G

A

H

H

Q

R

R

R

A

T

H

H

K

T

G

G

E

E

K

K

P

P

Y

Y

K

K

C

C

S

T

Y

W

E

E

G

G

C

C

D

T

K

W

A

K

F

F

A

A

R

R

A

S

H

D

D

E

C

L

K

T

R

R

H

H

E

F

L

R

L

K

H

H

L

T

G

G

V

I

R

K

K

P

Y

F

H

Q

C

C

S

P

P

D

C

C

N

D

R

R

D

S

F

F

V

S

R

R

L

S

D

D

-

H

-

L

A

A

L

L

H

H

R

R

Sites not aligning to the query:

60:68 9aaTAD; inactive

Q9Y4X4 Krueppel-like factor 12; Transcriptional repressor AP-2rep from Homo sapiens (Human) (see 2 papers)
47% identity, 95% coverage: 4:76/77 of query aligns to 322:396/402 of Q9Y4X4

query
sites
Q9Y4X4

E

E

L

G

C

C

G

N

E

K

T

V

F

Y

T

T

R

K

R

S

Y

S

N

H

L

L

R

K

G

A

H

H

Q

R

R

R

A

T

H

H

K

T

G

G

E

E

K

K

P

P

Y

Y

K

K

C

C

S

T

Y

W

E

E

G

G

C

C

D

T

K

W

A

K

F

F

A

A

R

R

A

S

H

D

D

E

C

L

K

T

R

R

H

H

E

Y

L

R

L

K

H

H

L

T

G

G

V

V

R

K

K

P

Y

F

H

K

C

C

S

A

P

D

C

C

N

D

R

R

D

S

F

F

V

S

R

R

L

S

D

D

-

H

-

L

A

A

L

L

H

H

R

R

Sites not aligning to the query:

80:88 9aaTAD; inactive
313 modified: N6-methylated lysine; by EHMT2

P08153 Transcriptional factor SWI5 from Saccharomyces cerevisiae (strain ATCC 204508 / S288c) (Baker's yeast) (see paper)
47% identity, 94% coverage: 6:77/77 of query aligns to 557:626/709 of P08153

query
sites
P08153

C

C

G

T

E

K

T

T

F

F

T

K

R

R

Y

Y

N

N

L

I

R

R

G

S

H

H

Q

I

R

Q

A

T

H

H

K

L

G

E

E

D

K

R

P

P

Y

Y

K

S

C

C

S

D

Y

H

E

P

G

G

C

C

D

D

K

K

A

A

F

F

A

V

R

R

A

N

H

H

D

D

C

L

K

I

R

R

H

H

E

K

L

K

L

S

H

H

L

Q

G

-

V

-

R

E

K

K

Y

A

H

Y

C

A

S

C

P

P

C

C

N

G

R

K

D

K

F

F

V

N

R

R

L

E

D

D

A

A

L

L

H

V

R

V

H

H

Sites not aligning to the query:

522 modified: Phosphoserine; by CDC28; S→A: Constitutive nuclear entry; when associated with A-646 and A-664.
646 modified: Phosphoserine; by CDC28; S→A: Constitutive nuclear entry; when associated with A-522 and A-664.
664 modified: Phosphoserine; by CDC28; S→A: Constitutive nuclear entry; when associated with A-522 and A-646.

O60481 Zinc finger protein ZIC 3; Zinc finger protein 203; Zinc finger protein of the cerebellum 3 from Homo sapiens (Human) (see 7 papers)
42% identity, 94% coverage: 6:77/77 of query aligns to 335:406/467 of O60481

query
sites
O60481

C

C

G

G

E
x
K

T

I

F

F

T

A

R
|
R

R

S

Y

E

N

N

L

L

R
x
K

G

I

H

H

Q
x
K

R
|
R

A

T

H

H

K

T

G

G

E

E

K
|
K

P

P

Y

F

K

K

C

C

S

E

Y

F

E

E

G

G

C

C

D

D

K

R

A

R

F

F

A

A

R

N

A

S

H

S

D

D

C

R

K

K

R

K

H

H

E

M

L

H

L

V

H

H

L

T

G

S

V

D

R

K

K

P

Y

Y

H

I

C

C

S

K

P

V

C

C

N

D

R

K

D

S

F

Y

V

T

R

H

L

P

D

S

A

S

L

L

H

R

R
x
K

H

H

K337 (≠ E8) mutation to A: Increases its cytoplasmic localization. Does not interact with KPNA1 and KPNA6 and increases strongly its cytoplasmic localization; when associated with A-320; A-341; A-346; A-349 and A-350.
R341 (= R12) mutation to A: Increases its cytoplasmic localization. Does not interact with KPNA1 and KPNA6 and increases strongly its cytoplasmic localization; when associated with A-320; A-337; A-346; A-349 and A-350.
K346 (≠ R17) mutation to A: Increases its cytoplasmic localization. Does not interact with KPNA1 and KPNA6 and increases strongly its cytoplasmic localization; when associated with A-320; A-337; A-341; A-349 and A-350.
K349 (≠ Q20) mutation to A: Increases its cytoplasmic localization. Does not interacts with KPNA1 and KPNA6 and increases strongly its cytoplasmic localization; when associated with A-320; A-337; A-341; A-346 and A-350.
R350 (= R21) mutation to A: Increases its cytoplasmic localization. Does not interact with KPNA1 and KPNA6 and increases strongly its cytoplasmic localization; when associated with A-320; A-337; A-341; A-346 and A-349.
K356 (= K27) mutation to A: Does not increase its cytoplasmic localization.
K405 (≠ R76) to E: in HTX1; lacks DNA-binding; does not inhibit transcriptional activation and interaction with GLI3; dbSNP:rs104894962

Sites not aligning to the query:

17 G → C: in HTX1 and CHTD1; uncertain significance; no effect on its transcriptional activator activity or subcellular localization; dbSNP:rs147232392
53 natural variant: A -> AA (in CHTD1; uncertain significance; no effect on its transcriptional activator activity or subcellular localization)
109 S → C: in CHTD1; does not affect its transcriptional activator activity; decrease in nuclear localization; dbSNP:rs373628598
217 P → A: in HTX1 and CHTD1; lacks DNA-binding; does not inhibit transcriptional activation and interaction with GLI3; decrease in nuclear localization; dbSNP:rs104894963
253 C → S: in HTX1; increases strongly its cytoplasmic localization; lacks DNA-binding; does not inhibit transcriptional activation and interaction with GLI3; dbSNP:rs104894961
255 W → G: in HTX1; decreases protein expression and transcriptional activity and increases its cytoplasmic localization; dbSNP:rs122463168
268 C→S: Increases weakly its cytoplasmic localization.
281 H→R: Increases its cytoplasmic localization.
286 H → R: in HTX1; inreases weakly its cytoplasmic localization; lacks DNA-binding; does not inhibit transcriptional activation and interaction with GLI3
304 R→M: Increases its cytoplasmic localization.
307 K→M: Increases its cytoplasmic localization.
310 K→M: Increases its cytoplasmic localization.
312 K→M: Increases its cytoplasmic localization.
314 K→M: Does not increase its cytoplasmic localization.
318 H → N: in VACTERLX; decrease in transcriptional activator activity; significant decrease in nuclear localization
320 R→A: Increases its cytoplasmic localization. Does not interact with KPNA1 and KPNA6 and increases strongly its cytoplasmic localization; when associated with A-337; A-341; A-346; A-349 and A-350.
323 T → M: in HTX1; lacks DNA-binding; does not inhibit transcriptional activation and interaction with GLI3; dbSNP:rs122462165
326 K→M: Does not increase its cytoplasmic localization.
447 A → G: in CHTD1; Increase in transcriptional activator activity; decrease in nuclear localization

P07247 Protein krueppel from Drosophila melanogaster (Fruit fly) (see paper)
44% identity, 100% coverage: 1:77/77 of query aligns to 222:296/502 of P07247

query
sites
P07247

F

F

V

T

C

C

E

K

L

I

C

C

G

S

E

R

T

S

F

F

T

G

R

Y

R

K

Y

H

N

V

L

L

R

Q

G

N

H

H

Q

E

R

R

A

T

H

H

K

T

G

G

E

E

K

K

P

P

Y

F

K

E

C

C

S

P

Y

E

E

-

G

-

C

C

D

H

K

K

A

R

F

F

A

T

R

R

A

D

H

H

D

H

C

L

K

K

R

T

H

H

E

M

L

R

L

L

H

H

L

T

G

G

V

E

R

K

K

P

Y

Y

H

H

C

C

S

S

P

H

C

C

N

D

R

R

D

Q

F

F

V

V

R

Q

L

V

D

A

A

N

L

L

H

R

R

R

H

H

Sites not aligning to the query:

468 modified: Phosphoserine
471 modified: Phosphoserine
477 modified: Phosphoserine

Q9XW26 Specificity protein transcription factor 3 from Caenorhabditis elegans (see paper)
37% identity, 99% coverage: 2:77/77 of query aligns to 317:392/412 of Q9XW26

query
sites
Q9XW26

V

I

C

C

E

H

L

L

C

C

G

N

E

K

T

T

F

Y

T

G

R

K

R

T

Y

S

N

H

L

L

R

R

G

A

H

H

Q

L

R

R

A

G

H

H

K

A

G

G

E

N

K

K

P

P

Y
x
F

K

A

C

C

S

D

Y

W

E

Q

G

H

C

C

D

N

K

K

A

K

F

F

A

T

R

R

A

S

H

D

D

E

C

L

K

Q

R

R

H

H

E

R

L

R

L

T

H

H

L

T

G

G

V

E

R

K

K

R

Y

F

H

A

C

C

S

N

P

H

C

C

N

G

R

K

D

K

F

F

V

M

R

R

L

S

D

D

A

H

L

L

H

T

R

K

H

H

F344 (≠ Y29) mutation to I: In gu85; fails to bind DNA. Defects in the morphology of vulval structures, resulting in protruding vulva and occasional bivulva phenotypes in adults. Reduced brood size. Embryonic and L1 larval arrest and morphological defects.

1meyC Crystal structure of a designed zinc finger protein bound to DNA (see paper)
43% identity, 100% coverage: 1:77/77 of query aligns to 4:78/83 of 1meyC

query
sites
1meyC

F

Y

V

K

C
|
C

E

P

L
x
E

C
|
C

G

G

E

K

T

S

F

F

T

S

R
x
Q

R

S

Y
x
S

N
|
N

L

L

R

Q

G
x
K

H
|
H

Q

Q

R

R

A
x
T

H
|
H

K
x
T

G

G

E

E

K

K

P

P

Y
|
Y

K

K

C
|
C

S

P

Y

E

E

-

G

-

C
|
C

D

G

K
|
K

A

S

F

F

A

S

R
x
Q

A

S

H
x
S

D
|
D

C

L

K

Q

R
x
K

H
|
H

E

Q

L

R

L

T

H
|
H

L

T

G

G

V

E

R

K

K

P

Y

Y

H

K

C
|
C

S

P

P

E

C

C

N

G

R
x
K

D

S

F

F

V

S

R
|
R

L

S

D
|
D

A
x
H

L

L

H

S

R
|
R

H
|
H

binding zinc ion: C6 (= C3), C9 (= C6), H22 (= H19), H26 (= H23), C34 (= C31), C37 (= C36), H50 (= H49), H54 (= H53), C62 (= C61), H78 (= H77)
binding : Q15 (≠ R12), S17 (≠ Y14), N18 (= N15), K21 (≠ G18), H22 (= H19), T25 (≠ A22), Y32 (= Y29), K39 (= K38), Q43 (≠ R42), S45 (≠ H44), D46 (= D45), K49 (≠ R48), H50 (= H49), K67 (≠ R66), R71 (= R70), D73 (= D72), H74 (≠ A73), R77 (= R76), H78 (= H77)
binding : E8 (≠ L5), T25 (≠ A22), H26 (= H23), T27 (≠ K24)

Sites not aligning to the query:

binding zinc ion: 82

1meyF Crystal structure of a designed zinc finger protein bound to DNA (see paper)
43% identity, 100% coverage: 1:77/77 of query aligns to 5:79/84 of 1meyF

query
sites
1meyF

F

Y

V

K

C
|
C

E

P

L

E

C
|
C

G

G

E
x
K

T

S

F
|
F

T

S

R
x
Q

R

S

Y
x
S

N
|
N

L

L

R
x
Q

G
x
K

H
|
H

Q

Q

R

R

A
x
T

H
|
H

K

T

G

G

E

E

K

K

P

P

Y
|
Y

K

K

C
|
C

S

P

Y

E

E

-

G

-

C
|
C

D

G

K

K

A

S

F

F

A

S

R
x
Q

A

S

H
x
S

D
|
D

C

L

K

Q

R

K

H
|
H

E

Q

L

R

L
x
T

H
|
H

L

T

G

G

V

E

R

K

K

P

Y

Y

H

K

C
|
C

S

P

P

E

C
|
C

N

G

R

K

D

S

F

F

V

S

R
|
R

L

S

D

D

A
x
H

L

L

H

S

R
|
R

H
|
H

binding zinc ion: C7 (= C3), C10 (= C6), H23 (= H19), H27 (= H23), C35 (= C31), C38 (= C36), H51 (= H49), H55 (= H53), C63 (= C61), C66 (= C64), H79 (= H77)
binding : K12 (≠ E8), F14 (= F10), Q16 (≠ R12), S18 (≠ Y14), N19 (= N15), Q21 (≠ R17), K22 (≠ G18), H23 (= H19), T26 (≠ A22), Y33 (= Y29), Q44 (≠ R42), S46 (≠ H44), D47 (= D45), H51 (= H49), T54 (≠ L52), R72 (= R70), H75 (≠ A73), R78 (= R76), H79 (= H77)

Sites not aligning to the query:

binding zinc ion: 83
binding : 82

O43623 Zinc finger protein SNAI2; Neural crest transcription factor Slug; Protein snail homolog 2 from Homo sapiens (Human) (see 3 papers)
42% identity, 99% coverage: 2:77/77 of query aligns to 186:259/268 of O43623

query
sites
O43623

V

V

C

C

E

K

L

I

C

C

G

G

E
x
K

T

A

F

F

T

S

R
|
R

R

P

Y

W

N

L

L

L

R

Q

G

G

H

H

Q

I

R

R

A

T

H

H

K

T

G

G

E

E

K

K

P

P

Y

F

K

S

C

C

S

P

Y

H

E

-

G

-

C

C

D

N

K

R

A

A

F

F

A

A

R

D

A
x
R

H

S

D

N

C

L

K
x
R

R

A

H

H

E

L

L

Q

L

T

H

H

L

S

G

D

V

V

R

K

K

K

Y

Y

H

Q

C

C

S

K

P

N

C

C

N

S

R

K

D

T

F

F

V

S

R

R

L

M

D

S

A

L

L

L

H

H

R

K

H

H

K192 (≠ E8) mutation to E: Abolishes binding to KPNA2 and impairs binding to KPNB1, IPO7 and TMPO1; when associated with E-196.
R196 (= R12) mutation to E: Abolishes binding to KPNA2 and impairs binding to KPNB1, IPO7 and TMPO1; when associated with E-192.
R225 (≠ A43) mutation to E: Abolishes binding to KPNA2, KPNB1 and IPO7 and impairs binding to TMPO1; when associated with E-229.
R229 (≠ K47) mutation to E: Abolishes binding to KPNA2, KPNB1 and IPO7 and impairs binding to TMPO1; when associated with E-225.

Sites not aligning to the query:

87 S→A: Increases protein stability. Does not affect repressor activity on E-cadherin/CDH1 promoter.
92 S→A: Increases protein stability, nuclear accumulation and repressor activity on E-cadherin/CDH1 promoter; when associated with A-96.
96 S→A: Increases protein stability, nuclear accumulation and repressor activity on E-cadherin/CDH1 promoter; when associated with A-92.
100 S→A: Increases protein stability and half-life, nuclear accumulation and repressor activity on E-cadherin/CDH1 promoter; when associated with A-104.
104 S→A: Increases protein stability and half-life, nuclear accumulation and repressor activity on E-cadherin/CDH1 promoter; when associated with A-100.
119 D → E: in a patient with neural tube defects; dbSNP:rs748917911
166 K→E: Abolishes binding to KPNA2, KPNB1 and IPO7 and impairs binding to TMPO1; when associated with E-175.
175 K→E: Abolishes binding to KPNA2, KPNB1 and IPO7 and impairs binding to TMPO1; when associated with E-166.

2ebtA Solution structure of three tandem repeats of zf-c2h2 domains from human kruppel-like factor 5
46% identity, 94% coverage: 6:77/77 of query aligns to 23:94/100 of 2ebtA

query
sites
2ebtA

C
|
C

G

T

E

K

T

V

F

Y

T

T

R

K

R

S

Y

S

N

H

L

L

R

K

G

A

H
|
H

Q

L

R

R

A

T

H
|
H

K

T

G

G

E

E

K

K

P

P

Y

Y

K

K

C
|
C

S

T

Y

W

E

E

G

G

C
|
C

D

D

K

W

A

R

F

F

A

A

R

R

A

S

H

D

D

E

C

L

K

T

R

R

H
|
H

E

Y

L

R

L

K

H
|
H

L

T

G

G

V

A

R

K

K

P

Y

F

H

Q

C
|
C

S

G

P

V

C
|
C

N

N

R

R

D

S

F

F

V

S

R

R

L

S

D

D

A

H

L

L

H

A

R

L

H
|
H

binding zinc ion: C23 (= C6), H36 (= H19), H40 (= H23), C48 (= C31), C53 (= C36), H66 (= H49), H70 (= H53), C78 (= C61), C81 (= C64), H94 (= H77)

Sites not aligning to the query:

binding zinc ion: 18, 98

O95863 Zinc finger protein SNAI1; Protein snail homolog 1; Protein sna from Homo sapiens (Human) (see 19 papers)
43% identity, 99% coverage: 2:77/77 of query aligns to 181:254/264 of O95863

query
sites
O95863

V
|
V

C
|
C

E
x
G

L
x
T

C
|
C

G
|
G

E
x
K

T
x
A

F
|
F

T
x
S

R
|
R

R
x
P

Y
x
W

N
x
L

L
|
L

R
x
Q

G
|
G

H
|
H

Q
x
V

R
|
R

A
x
T

H
|
H

K
x
T

G
|
G

E
|
E

K
|
K

P
|
P

Y
x
F

K
x
S

C
|
C

S
x
P

Y
x
H

E

-

G

-

C
|
C

D
x
S

K
x
R

A
|
A

F
|
F

A
|
A

R
x
D

A
x
R

H
x
S

D
x
N

C
x
L

K
x
R

R
x
A

H
|
H

E
x
L

L
x
Q

L
x
T

H
|
H

L
x
S

G
x
D

V
|
V

R
x
K

K
|
K

Y
|
Y

H
x
Q

C
|
C

S
x
Q

P
x
A

C
|
C

N
x
A

R
|
R

D
x
T

F
|
F

V
x
S

R
|
R

L
x
M

D
x
S

A
x
L

L
|
L

H
|
H

R
x
K

H
|
H

C182 (= C3) mutation to A: Impairs binding to KPNB1, IPO7 and TNPO1 and abolishes binding to KPNA2. Localizes to cytoplasm and nucleus.
K187 (≠ E8) mutation to E: Does not affect binding to KPNB1, KPNA2, IPO7 or TNPO1. Impairs binding to KPNB1, KPNA2, IPO7 and TNPO1 and abolishes nuclear localization, DNA binding and repressor activity on E-cadherin/CDH1 promoter; when associated with E-191. Abolishes binding to KPNB1, KPNA2, IPO7 and TNPO1 and nuclear localization; when associated with E-161 and/or E-220.
R191 (= R12) mutation to E: Mildly reduces binding to KPNB1 and nuclear import. Does not affect binding to KPNA2, IPO7 or TNPO1. Strongly reduces binding to KPNB1 and nuclear import; when associated with A-193. Loss of binding to KPNB1 and nuclear import; when associated with A-193 and A-196.
W193 (≠ Y14) mutation to A: Mildly reduces binding to KPNB1 and nuclear import. Strongly reduces binding to KPNB1 and nuclear import; when associated with E-191. Loss of binding to KPNB1 and nuclear import; when associated with E-191 and A-196.
Q196 (≠ R17) mutation to A: Loss of binding to KPNB1 and nuclear import; when associated with E-191 and A-193.
T203 (≠ K24) modified: Phosphothreonine; by LATS2; mutation to A: Abolishes LATS2 phosphorylation. Does not affect binding to LATS2. Reduces protein stability. Equally distributed between nucleus and cytoplasm. Increases capacity to associate with nuclear pore importins. Unable to accumulate in the nucleus. Does not abrogate function.; mutation to E: Exclusively localizes to the cytoplasm. Reduces capacity to associate with nuclear pore importins. Unable to enter the nucleus. Does not abrogate function.
C210 (= C31) mutation to A: Impairs binding to KPNB1, IPO7 and TNPO1 and abolishes binding to KPNA2. Localizes to cytoplasm and nucleus.
R215 (≠ K38) mutation to E: Impairs binding to KPNB1, KPNA2, IPO7 and TNPO1. No change in subcellular localization.
R220 (≠ A43) mutation to E: Does not affect binding to KPNB1, KPNA2, IPO7 or TNPO1. No change in subcellular localization. Impairs binding to KPNB1, KPNA2, IPO7 and TNPO1; when associated with E-222 and E-224. Impairs binding to KPNB1, KPNA2, IPO7 and TNPO1 and abolishes nuclear localization, DNA binding and repressor activity on E-cadherin/CDH1 promoter; when associated with E-224. Abolishes binding to KPNB1, KPNA2, IPO7 and TNPO1 and nuclear localization; when associated with E-161 and/or E-187.
N222 (≠ D45) mutation to E: Does not affect binding to KPNB1, KPNA2, IPO7 or TNPO1. No change in subcellular localization. Impairs binding to KPNB1, KPNA2, IPO7 and TNPO1; when associated with E-220 and E-224.
R224 (≠ K47) mutation to E: Does not affect binding to KPNB1, KPNA2, IPO7 or TNPO1. No change in subcellular localization. Impairs binding to KPNB1, KPNA2, IPO7 and TNPO1; when associated with E-220 and E-222. Impairs binding to KPNB1, KPNA2, IPO7 and TNPO1 and abolishes nuclear localization, DNA binding and repressor activity on E-cadherin/CDH1 promoter; when associated with E-220. Strongly reduces binding to KPNB1 and nuclear import; when associated with A-228.
Q228 (≠ L51) mutation to A: Very minor effect on binding to KPNB1 and nuclear import. Strongly reduces binding to KPNB1 and nuclear import; when associated with E-224.
DVKK 232:235 (≠ GVRK 55:58) mutation to KVEE: Does not affect binding to KPNB1, KPNA2, IPO7 or TNPO1.
C238 (= C61) mutation to A: Impairs binding to KPNB1 and IPO7 and abolishes binding to KPNA2 and TNPO1 and nuclear localization.
Q239 (≠ S62) mutation to E: Does not affect binding to KPNB1, KPNA2, IPO7, TNPO1 or DNA.
S246 (≠ V69) modified: Phosphoserine; by PAK1; mutation to A: Decreases repression activity on E-cadherin/CDH1, occludin and aromatase promoters. Preferentially localizes to the cytoplasm. Abolishes phosphorylation by PAK1.
R247 (= R70) mutation to E: Mildly reduces binding to KPNB1 and nuclear import.

Sites not aligning to the query:

2 P→A: Abolishes repressor activity on E-cadherin/CDH1 promoter and binding to KDM1A.
2:7 Required and sufficient for interaction with KDM1A
3 R→A: Loss of interaction with KDM1A.
4 S→A: Loss of interaction with KDM1A.
5 F→A: Loss of interaction with KDM1A.
8 R→A: Loss of interaction with KDM1A.
9 K→A: Loss of interaction with KDM1A.; K→R: Does not affect E-cadherin/CDH1 repression; when associated with R-16.
11 modified: Phosphoserine; by PKA; S→A: Abolishes PKA phosphorylation. Strongly decreases repressor activity on E-cadherin/CDH1 and CLDN1 promoters. Increases protein stability. Affects function in EMT.
16 K→R: Does not affect E-cadherin repression; when associated with R-9.
82 modified: Phosphoserine
92 modified: Phosphoserine; by CK2; S→A: Abolishes CK2 phosphorylation. Strongly decreases repressor activity on E-cadherin/CDH1 and CLDN1 promoters. Increases protein stability. Affects function in cell survival. Abolishes phosphorylation in the serine-rich region; when associated with A-104 and A-107.; S→E: Does not affect repressor activity on E-cadherin/CDH1 promoter.
96 modified: Phosphoserine; S→A: Abolishes recognition and ubiquitination by BTRC which increases steady state level and half-life. Preferentially localizes to the nucleus. Induces a more aggressive tissue invasion program. Lower sensitivity to BTRC-triggered degradation, impairs phosphorylation by GSK3B and does not affect NOTCH1-induced degradation; when associated with A-100. Lower sensitivity to BTRC-triggered degradation, impaired phosphorylation by GSK3B and loss of cytoplasmic localization; when associated with A-100; A-107; A-111; A-115 and A-119.
98 K→R: No change. Complete loss of sensitivity to FBXL14- and BTRC-triggered degradation and loss of ability to repress E-cadherin/CDH1; when associated with R-137 and R-146.
100 S→A: Lower sensitivity to BTRC-triggered degradation and impaired phosphorylation by GSK3B; when associated with A-96. Lower sensitivity to BTRC-triggered degradation, impaired phosphorylation by GSK3B and loss of cytoplasmic localization; when associated with A-96; A-107; A-111; A-115 and A-119. Does not affect NOTCH1-induced degradation; when associated with A-96. Abolishes phosphorylation at S-96.
104 modified: Phosphoserine; S→A: Increases protein stability, does not affect repressor activity on E-cadherin/CDH1 promoter, preferentially localizes to the nucleus, induces a more aggressive tissue invasion program and impairs phosphorylation by GSK3B, binding to BTRC and ubiquitination; when associated with A-107. Impairs phosphorylation in the serine-rich domain/region; when associated with A-92 and A-107. Abolishes phosphorylation at S-96.
107 modified: Phosphoserine; S→A: Lower sensitivity to BTRC-triggered degradation, impaired phosphorylation by GSK3B and loss of cytoplasmic localization; when associated with A-111; A-115 and A-119. Lower sensitivity to BTRC-triggered degradation, impaired phosphorylation by GSK3B and loss of cytoplasmic localization; when associated with A-96; A-100; A-111; A-115 and A-119. Increases protein stability, does not affect repressor activity on E-cadherin promoter, preferentially localizes to the nucleus, induces a more aggressive tissue invasion program and impairs phosphorylation by GSK3B, binding to BTRC and ubiquitination; when associated with A-104. Impairs phosphorylation in the serine-rich region; when associated with A-92 and A-104. Abolishes phosphorylation at S-96.; S→E: Predominantly localized to the cytoplasm; when associated with E-111; E-115 and E-119.
111 S→A: Lower sensitivity to BTRC-triggered degradation, impaired phosphorylation by GSK3B and loss of cytoplasmic localization; when associated with A-107; A-115 and A-119. Lower sensitivity to BTRC-triggered degradation, impaired phosphorylation by GSK3B and loss of cytoplasmic localization; when associated with A-96; A-100; A-107; A-115 and A-119.; S→E: Predominantly localized to the cytoplasm; when associated with E-107; E-115 and E-119.
112 modified: carbohydrate, O-linked (GlcNAc) serine
115 S→A: Lower sensitivity to BTRC-triggered degradation, impaired phosphorylation by GSK3B and loss of cytoplasmic localization; when associated with A-107; A-111 and A-119. Lower sensitivity to BTRC-triggered degradation, impaired phosphorylation by GSK3B and loss of cytoplasmic localization; when associated with A-96; A-100; A-107; A-111 and A-119.; S→E: Predominantly localized to the cytoplasm; when associated with E-107; E-111 and E-119.
118 V → A: in dbSNP:rs4647958
119 S→A: Lower sensitivity to BTRC-triggered degradation, impaired phosphorylation by GSK3B and loss of cytoplasmic localization; when associated with A-107; A-111 and A-119. Lower sensitivity to BTRC-triggered degradation, impaired phosphorylation by GSK3B and loss of cytoplasmic localization; when associated with A-96; A-100; A-107; A-111 and A-115.; S→E: Predominantly localized to the cytoplasm; when associated with E-107; E-111 and E-115.
137 K→R: Lower sensitivity to FBXL14-triggered degradation. Lower sensitivity to FBXL14-triggered degradation; when associated with R-146. Complete loss of sensitivity to FBXL14- and BTRC-triggered degradation and loss of ability to repress E-cadherin; when associated with R-98 and R-146.
146 K→R: Lower sensitivity to FBXL14-triggered degradation. Lower sensitivity to FBXL14-triggered degradation; when associated with R-137. Complete loss of sensitivity to FBXL14- and BTRC-triggered degradation; when associated with R-98 and R-137.
151:152 RK→EE: Does not affect binding to KPNB1, KPNA2, IPO7 or TNPO1.
151:264 Required for nuclear localization and interaction with KPNB1, NOTCH1 and PARP1
156 C→A: Abolishes binding to KPNB1, KPNA2, IPO7 and TNPO1 and nuclear localization.
161 K→E: Does not affect binding to KPNB1, KPNA2, IPO7 or TNPO1. No change in subcellular localization. Impairs binding to KPNB1, KPNA2, IPO7 and TNPO1 and abolishes nuclear localization, DNA binding and repressor activity on E-cadherin/CDH1 promoter; when associated with E-170. Abolishes binding to KPNB1, KPNA2, IPO7 and TNPO1 and nuclear localization; when associated with E-187 and/or E-220.
170 K→E: Does not affect binding to KPNB1, KPNA2, IPO7 or TNPO1. No change in subcellular localization. Impairs binding to KPNB1, KPNA2, IPO7 and TNPO1 and abolishes nuclear localization, DNA binding and repressor activity on E-cadherin/CDH1 promoter; when associated with E-161.

O75840 Krueppel-like factor 7; Ubiquitous krueppel-like factor from Homo sapiens (Human) (see 2 papers)
46% identity, 94% coverage: 6:77/77 of query aligns to 226:297/302 of O75840

query
sites
O75840

C

C

G

R

E

K

T

V

F

Y

T

T

R

K

R

S

Y

S

N

H

L

L

R

K

G

A

H

H

Q

Q

R

R

A

T

H

H

K

T

G

G

E

E

K

K

P

P

Y

Y

K

K

C

C

S

S

Y

W

E

E

G

G

C

C

D

E

K

W

A

R

F

F

A

A

R

R

A

S

H
x
D

D

E

C

L

K

T

R

R

H

H

E

Y

L

R

L

K

H

H

L

T

G

G

V

A

R

K

K

P

Y

F

H

K

C

C

S

N

P

H

C

C

N

D

R

R

D

C

F

F

V

S

R

R

L

S

D

D

A

H

L

L

H

A

R

L

H

H

D264 (≠ H44) to N: found in a patient with developmental delay/intellectual disability, neuromuscular and psychiatric symptoms; uncertain significance; dbSNP:rs1057518995

Sites not aligning to the query:

93:101 9aaTAD; inactive
137 T → M: found in two patients with developmental delay/intellectual disability, neuromuscular and psychiatric symptoms; uncertain significance; dbSNP:rs1276619385
139 P → S: found in a patient with developmental delay/intellectual disability, neuromuscular and psychiatric symptoms; uncertain significance

6ml4A Btb24 zinc fingers 4-8 with 19+1mer DNA oligonucleotide (sequence 3) (see paper)
44% identity, 100% coverage: 1:77/77 of query aligns to 61:135/143 of 6ml4A

query
sites
6ml4A

F

F

V

T

C
|
C

E

E

L

I

C
|
C

G

G

E

K

T

S

F
|
F

T
|
T

R

A

R

K

Y

S

N
x
S

L

L

R

Q

G

T

H
|
H

Q

I

R

R

A
x
I

H
|
H

K

R

G

G

E

E

K

K

P

P

Y

Y

K

S

C
|
C

S

S

Y

I

E

-

G

-

C
|
C

D

G

K

K

A

C

F

F

A

S

R
x
D

A

S

H
x
S

D

A

C

K

K
x
R

R
|
R

H
|
H

E

C

L

I

L
|
L

H
|
H

L

T

G

G

V

K

R

K

K

P

Y

F

H

S

C
|
C

S

P

P

E

C
|
C

N

G

R

L

D

Q

F
|
F

V

A

R
|
R

L

L

D
|
D

A
x
N

L

L

H
x
K

R

A

H
|
H

binding zinc ion: C63 (= C3), C66 (= C6), H79 (= H19), H83 (= H23), C91 (= C31), C94 (= C36), H107 (= H49), H111 (= H53), C119 (= C61), C122 (= C64), H135 (= H77)
binding : F70 (= F10), T71 (= T11), S75 (≠ N15), H79 (= H19), I82 (≠ A22), D100 (≠ R42), S102 (≠ H44), R105 (≠ K47), R106 (= R48), H107 (= H49), L110 (= L52), F126 (= F68), R128 (= R70), D130 (= D72), N131 (≠ A73), K133 (≠ H75), H135 (= H77)

Sites not aligning to the query:

binding zinc ion: 7, 10, 23, 27, 35, 38, 51, 55, 139
binding : 19, 44, 45, 46, 47, 47, 49, 50, 51, 54, 59

Q99612 Krueppel-like factor 6; B-cell-derived protein 1; Core promoter element-binding protein; GC-rich sites-binding factor GBF; Proto-oncogene BCD1; Suppressor of tumorigenicity 12 protein; Transcription factor Zf9 from Homo sapiens (Human) (see 3 papers)
46% identity, 94% coverage: 6:77/77 of query aligns to 207:278/283 of Q99612

query
sites
Q99612

C

C

G

R

E

K

T

V

F

Y

T

T

R

K

R

S

Y

S

N

H

L

L

R

K

G

A

H

H

Q

Q

R

R

A

T

H

H

K

T

G

G

E

E

K

K

P

P

Y

Y

K

R

C

C

S

S

Y

W

E

E

G

G

C

C

D

E

K

W

A

R

F

F

A

A

R

R

A

S

H

D

D

E

C

L

K

T

R

R

H

H

E

F

L

R

L

K

H

H

L

T

G

G

V

A

R

K

K

P

Y

F

H

K

C

C

S

S

P

H

C

C

N

D

R

R

D

C

F

F

V

S

R

R

L

S

D

D

A

H

L

L

H

A

R

L

H

H

Sites not aligning to the query:

62:70 9aaTAD; inactive
64 W → R: found in prostate cancer samples; somatic mutation; does not up-regulates CDKN1A in a p53-independent manner and significantly reduces cell proliferation; dbSNP:rs121909142
116 S → P: found in prostate cancer samples; somatic mutation; does not up-regulates CDKN1A in a p53-independent manner and significantly reduces cell proliferation; dbSNP:rs121909139
123 A → D: found in prostate cancer samples; somatic mutation; does not up-regulates CDKN1A in a p53-independent manner and significantly reduces cell proliferation; dbSNP:rs121909141
155 S → R: found in gastric cancer samples; somatic mutation; dbSNP:rs121909144
169 L → P: found in prostate cancer samples; somatic mutation; does not up-regulates CDKN1A in a p53-independent manner and significantly reduces cell proliferation; dbSNP:rs121909143
172 P → T: found in gastric cancer samples; somatic mutation
180 S → L: found in gastric cancer samples; somatic mutation; dbSNP:rs372338890
198 R → K: found in gastric cancer samples; somatic mutation

2i13B Aart, a six finger zinc finger designed to recognize ann triplets (see paper)
43% identity, 100% coverage: 1:77/77 of query aligns to 59:133/144 of 2i13B

query
sites
2i13B

F

Y

V

K

C
|
C

E

P

L

E

C
|
C

G

G

E
x
K

T

S

F
|
F

T

S

R
x
Q

R
|
R

Y

A

N
|
N

L

L

R
|
R

G

A

H
|
H

Q

Q

R

R

A
x
T

H
|
H

K

T

G

G

E

E

K

K

P

P

Y

Y

K

A

C
|
C

S

P

Y

E

E

-

G

-

C
|
C

D

G

K

K

A

S

F
|
F

A

S

R
x
Q

A

L

H

A

D
x
H

C

L

K

R

R

A

H
|
H

E

Q

L

R

L
x
T

H
|
H

L

T

G

G

V

E

R

K

K

P

Y

Y

H

K

C
|
C

S

P

P

E

C
|
C

N

G

R

K

D

S

F
|
F

V

S

R
|
R

L

E

D
|
D

A
x
N

L

L

H

H

R

T

H
|
H

binding zinc ion: C61 (= C3), C64 (= C6), H77 (= H19), H81 (= H23), C89 (= C31), C92 (= C36), H105 (= H49), H109 (= H53), C117 (= C61), C120 (= C64), H133 (= H77)
binding : K66 (≠ E8), F68 (= F10), Q70 (≠ R12), R71 (= R13), N73 (= N15), R75 (= R17), H77 (= H19), T80 (≠ A22), F96 (= F40), Q98 (≠ R42), H101 (≠ D45), H105 (= H49), T108 (≠ L52), F124 (= F68), R126 (= R70), D128 (= D72), N129 (≠ A73), H133 (= H77)

Sites not aligning to the query:

binding zinc ion: 5, 8, 21, 25, 33, 36, 49, 53, 137
binding : 10, 12, 14, 16, 17, 21, 24, 40, 45, 48, 49, 52, 136, 139, 141

Query Sequence

>13241
FVCELCGETFTRRYNLRGHQRAHKGEKPYKCSYEGCDKAFARAHDCKRHELLHLGVRKYH
CSPCNRDFVRLDALHRH

Or try a new SitesBLAST search

SitesBLAST's Database

SitesBLAST's database includes (1) SwissProt entries with experimentally-supported functional features; and (2) protein structures with bound ligands, from the BioLip database.

by Morgan Price, Arkin group
Lawrence Berkeley National Laboratory